OBJECTIVE: To investigate the role of @entity172 deprivation and replacement in amenorrheic and nonamenorrheic dancers on hormone therapy and @entity460 . DESIGN: Clinical, placebo-controlled, randomized trial study.Healthy volunteers in an academic research environment. @entity1 (S): Fifty-five dancers (mean age: 22.0 +/- 4.6, age at menarche: 14.7 +/- 2.3 years), including 24 amenorrheics. INTERVENTION(S): Amenorrheics were randomized in a controlled trial to receive placebo or @entity17916 , 0.625 mg for 25 days monthly, with Provera, 10 mg, for 10 of these 25 days (hormone therapy) for 2 years. These @entity1 were compared to normally menstruating controls. The study @entity1 also received 1250 mg of @entity460 per day. MAIN OUTCOME MEASURE(S): @entity79 ( @entity79 ) measured at the foot, wrist, and lumbar spine. Our overall results showed no difference in @entity79 between the treated or placebo groups, indicating that hormone therapy did not change or normalize @entity79 when compared to normals. Five @entity1 (all on placebo) who resumed menses during the study showed an increase in @entity79 without normalization. CONCLUSION(S): These findings suggest that mechanisms other than hypoestrogenism may be involved with the @entity2331 associated with exercise-induced @entity2588 .

Persistent XXXX in ballet dancers with @entity2588 and delayed menarche despite hormone therapy: a longitudinal study.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'PATIENT'] @entity17916 :: ('MESH:D004966', 'Chemical') :: ['Premarin'] @entity79 :: ('MESH:D001847', 'Disease') :: ['Bone mineral density', 'BMD'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']
@entity2331 :: (MESH:D001851,Disease) :: ['osteopenia']
